You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Attention Score in Context
| Title |
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, May 2023
|
| DOI | 10.1007/s00262-023-03469-5 |
| Pubmed ID | |
| Authors |
Matteo Santoni, Zin W. Myint, Thomas Büttner, Hideki Takeshita, Yohei Okada, Elaine T. Lam, Danielle Gilbert, Zsófia Küronya, Deniz Tural, Renate Pichler, Enrique Grande, Simon J. Crabb, Robert Kemp, Francesco Massari, Sarah Scagliarini, Roberto Iacovelli, Nuno Vau, Umberto Basso, Marco Maruzzo, Javier Molina-Cerrillo, Luca Galli, Aristotelis Bamias, Ugo De Giorgi, Paolo Andrea Zucali, Mimma Rizzo, Emmanuel Seront, Lazar Popovic, Orazio Caffo, Sebastiano Buti, Ravindran Kanesvaran, Jindrich Kopecky, Jakub Kucharz, Annalisa Zeppellini, Ondřej Fiala, Johannes Landmesser, Jawaher Ansari, Patrizia Giannatempo, Alessandro Rizzo, Ignacio Ortego Zabalza, Fernando Sabino M. Monteiro, Nicola Battelli, Fabio Calabrò, Camillo Porta |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 5 | 28% |
| Italy | 2 | 11% |
| Brazil | 2 | 11% |
| Mexico | 1 | 6% |
| Argentina | 1 | 6% |
| Turkey | 1 | 6% |
| Unknown | 6 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 50% |
| Practitioners (doctors, other healthcare professionals) | 8 | 44% |
| Scientists | 1 | 6% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2023.
All research outputs
#3,137,714
of 24,962,233 outputs
Outputs from Cancer Immunology, Immunotherapy
#209
of 2,953 outputs
Outputs of similar age
#55,828
of 372,690 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#2
of 20 outputs
Altmetric has tracked 24,962,233 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,953 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 372,690 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.